Elite in Obesity in Children

C Maffeis-Claudio

Verona, IT 
Elite in Obesity in Children
Verona, IT 
OverviewLocationsClinical Research

Overview

C Maffeis-Claudio practices in Verona, Italy. Maffeis-Claudio and is rated as an Elite expert by MediFind in the treatment of Obesity in Children. Their top areas of expertise are Obesity in Children, Obesity, Type 1 Diabetes (T1D), and Congenital Hyperinsulinism.

Their clinical research consists of co-authoring 264 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 77 articles in the study of Obesity in Children.

Locations

Verona, Italy
Other Locations
Turin, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both
Enrollment Status: Completed
Publish Date: February 26, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro
Study Phase: Phase 3
View 1 Less Clinical Trial

264 Total Publications

Omnipod 5 in children and adolescents with type 1 diabetes: Improved outcomes with fewer boluses.
Omnipod 5 in children and adolescents with type 1 diabetes: Improved outcomes with fewer boluses.
Journal: Diabetes, obesity & metabolism
Published: March 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Maffeis-Claudio's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile